Reinsurance Group of America, Incorporated RGA
Composite 61/100; the shares have moved about 21% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Balance-sheet strength ranks 43/100 — a slight mark against it.
Valuation ranks 89/100 — a strong point in its favour. Momentum ranks 78/100 — a strong point in its favour. Growth ranks 58/100 — a slight point in its favour.
Balance-sheet strength ranks 43/100 — a slight mark against it. Quality ranks 46/100 — a slight mark against it.
What the company does Reinsurance Group of America (RGA) provides life, health, disability, long-term care, critical illness, and asset-intensive reinsurance across global markets. It also offers longevity reinsurance, pension risk transfers, and capital solutions, serving insurers and pension funds.
Key financials RGA’s profitability metrics include ROE 9.9%, ROA 0.9%, and net margins 4.9%. Revenue and EPS grew 23.5% and 16.6%, respectively. Debt/Equity is 0.46, and the current ratio is 1.12. The dividend yield is 1.5% with a 20.0% payout ratio.
Stock health Sideravia scores RGA’s overall quality as 58.9, with valuation at 86.5 and momentum at 69.5. The stock is up 27.24% over 12 months but down 2.87% from its 52-week high. RSI(14) is 60.50, indicating moderate bullish momentum.
Price vs fair value The stock trades at a **discount** of 53.10% versus our fair-value estimate and a **discount** of 10.00% versus the analyst 12-month target. - Trading at steep discounts to both fair value and analyst targets (Sideravia, Zacks) - Analysts highlight expected earnings growth (Zacks) - Valuation metrics (P/E 12.99, PEG 1.14) suggest undervaluation relative to growth
Looking forward Forward P/E of 8.28 and PEG of 0.15 imply potential upside if growth materializes. Momentum remains positive, but quality scores (42.2) suggest execution risk. Monitor pension risk transfer and longevity reinsurance pipelines for catalysts.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.